Noncanonical NF-κB pathway driven inflammation across multiple cellular compartments identifies NIK as a therapeutic target for inflammatory bowel disease - Report - MDSpire

Noncanonical NF-κB pathway driven inflammation across multiple cellular compartments identifies NIK as a therapeutic target for inflammatory bowel disease

  • By

  • Hao Xu

  • Dun Li

  • Jie Liang

  • Nathan Adamson

  • Alexis Scherl

  • Luli Zou

  • Crystal Hu

  • Elaine E. Storm

  • Christian B. Cox

  • Adam Johnson

  • Mary E. Keir

  • Hua Zhang

  • Saiyu Hang

  • June 9, 2026

  • 0 min

Share

Targeting NIK in the Noncanonical NF-κB Pathway Reveals Inflammatory Mechanisms

Overview

This study investigates the role of NF-κB-inducing kinase (NIK) in inflammatory bowel disease (IBD) and evaluates a small molecule NIK inhibitor (NIK-smi) in preclinical models.

Background

Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, is characterized by chronic inflammation of the gastrointestinal tract. The noncanonical NF-κB pathway, driven by NIK, is implicated in the pathogenesis of IBD.

Data Highlights

No numerical data provided in the source material.

Key Findings

  • NIK deletion in epithelial cells disrupts M-cell differentiation and reduces CCL20-mediated recruitment of Th17 cells and ILC3s.
  • NIK activity in dendritic cells amplifies CD40-mediated innate immune responses.
  • NIK skews T cell differentiation toward pro-inflammatory Th1 cells, reducing regulatory T cells.
  • Systemic NIK deletion and pharmacologic inhibition with NIK-smi attenuate inflammation in preclinical colitis models.
  • NIK-smi treatment reduces immune cell infiltration and pro-inflammatory cytokines, improving colon histopathology.
  • Optimal dosing regimen for NIK-smi identified as 200 mg/kg BID.

Clinical Implications

The findings suggest that targeting NIK may provide a new therapeutic approach for managing IBD. Further exploration of NIK inhibitors could enhance treatment options for patients with IBD, particularly those unresponsive to current therapies.

Conclusion

NIK plays a significant role in the inflammatory processes of IBD, and its pharmacologic inhibition presents a promising strategy for therapeutic intervention. Future studies are warranted to further evaluate NIK-targeted therapies in clinical settings.

Related Resources & Content

  1. Author(s)/Org, Source, Year -- Title
  2. Author(s)/Org, Source, Year -- Title
  3. Author(s)/Org, Source, Year -- Title
  4. Author(s)/Org, Source, Year -- Title
  5. American Gastroenterological Association, Living guideline for pharmacological management of moderate-to-severe ulcerative colitis, 2024 -- Current guidelines
  6. Author(s)/Org, Source, Year -- Title
  7. Author(s)/Org, Source, Year -- Title
  8. Living guideline for pharmacological management of moderate-to-severe ulcerative colitis - American Gastroenterological Association
  9. Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to Severely Active Crohn’s Disease: Results From the Phase 3 GRAVITI Study - ScienceDirect
  10. NF-κB in inflammation and cancer | Cellular & Molecular Immunology

Original Source(s)

Noncanonical NF-κB pathway driven inflammation across multiple cellular compartments identifies NIK as a therapeutic target for inflammatory bowel disease

  • by Hao Xu, Dun Li, Jie Liang, Nathan Adamson, Alexis Scherl, Luli Zou, Crystal Hu, Elaine E. Storm, Christian B. Cox, Adam Johnson, Mary E. Keir, Hua Zhang, Saiyu Hang

  • June 9, 2026

Related Content

Evaluation of 5-Aminosalicylic Acid Utilization in Crohn’s Disease Management: Insights from a Nationwide Survey of Inflammatory Bowel Disease Specialists

Side Effects: Four Studies Worth Passing On

Kissing celiacs, Ozempic genes, Viagra for the brain, and a UTI test that actually works. This week's evidence is weird, useful, and worth your time.

Evidence-based summary of optimal home self-management for elderly ostomy patients